Characterization of Sigma-2 Receptor—Specific Binding Sites Using [3H]DTG and [125I]RHM-4
Open Access
- 15 December 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (12) , 1564
Abstract
The sigma-2 receptor/transmembrane protein 97 (σ2R/TMRM97) is a promising biomarker of tumor proliferation and a target for cancer therapy. [3H]DTG has been used to evaluate σ2R/TMEM97 binding affinity in compound development studies. However, [3H]DTG has equal and moderate binding affinities to both sigma 1 receptor (σ1R) and σ2R/TMEM97. Furthermore, co-administration with the σ1R masking compound (+)-pentazocine may cause bias in σ2R/TMEM97 binding affinity screening experiments. We have developed a radioiodinated ligand, [125I]RHM-4, which has high affinity and selectivity for σ2R/TMEM97 versus σ1R. In this study, a head-to-head comparison between [3H]DTG and [125I]RHM-4 on the binding affinity and their effectiveness in σ2R/TMEM97 compound screening studies was performed. The goal of these studies was to determine if this radioiodinated ligand is a suitable replacement for [3H]DTG for screening new σ2R/TMEM97 compounds. Furthermore, to delineate the binding properties of [125I]RHM-4 to the σ2R/TMEM97, the structure of RHM-4 was split into two fragments. This resulted in the identification of two binding regions in the σ2R, the “DTG” binding site, which is responsible for binding to the σ2R/TMEM97, and the secondary binding site, which is responsible for high affinity and selectivity for the σ2R/TMEM97 versus the σ1R. The results of this study indicate that [125I]RHM-4 is an improved radioligand for in vitro binding studies of the σ2R/TMEM97 versus [3H]DTG.Keywords
Funding Information
- the Department of Radiology at the University of Pennsylvania, the Ministry of Science and Technology, Taiwan (MOST 110-2314-B-182-029)
- Chang Gung Memorial Hospital (CMRPD1K0012)
- Healthy Aging Research Center (EMRPD1M0451)
This publication has 38 references indexed in Scilit:
- Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding siteNature Communications, 2011
- Synthesis and Pharmacological Evaluation of Fluorine-Containing D3Dopamine Receptor LigandsJournal of Medicinal Chemistry, 2011
- ς1 Receptor Modulation of Opioid Analgesia in the MouseThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Cloning and Characterization of a Mouse σ1 ReceptorJournal of Neurochemistry, 1998
- Cloning and Structural Analysis of the cDNA and the Gene Encoding the Murine Type 1 Sigma ReceptorBiochemical and Biophysical Research Communications, 1997
- Cloning and Functional Expression of the Human Type 1 Sigma Receptor (hSigmaR1)Biochemical and Biophysical Research Communications, 1996
- Rat liver and kidney contain high densities of σ1 and σ2 receptors: characterization by ligand binding and photoaffinity labelingEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- Characterization of the binding of [3H](+)-pentazocine to σ recognition sites in guinea pig brainEuropean Journal of Pharmacology: Molecular Pharmacology, 1992
- A proposal for the classification of sigma binding sitesTrends in Pharmacological Sciences, 1992
- Mouse ascites Sarcoma 180 thymidylate kinase. General properties, kinetic analysis, and inhibition studiesBiochemistry, 1973